Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone

Journal of Neurochemistry

Volumn 101, Issue 6, 2007, Pages 1491-1504

  Inden, Masatoshi ^a   Kitamura, Yoshihisa ^a   Takeuchi, Hiroki ^b   Yanagida, Takashi ^a   Takata, Kazuyuki ^a   Kobayashi, Yuka ^a   Taniguchi, Takashi ^a   Yoshimoto, Kanji ^c   Kaneko, Masahiko ^d   Okuma, Yasunobu ^d   Taira, Takahiro ^e   Ariga, Hiroyoshi ^f   Shimohama, Shun ^b,g  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY   (Japan)

^d CHIBA INSTITUTE OF SCIENCE   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

synuclein; 4 phenylbutyrate; C57BL 6 mouse; Parkinson's disease; Rotenone; Substantia nigra

Indexed keywords

4 PHENYLBUTYRIC ACID; ALPHA SYNUCLEIN; ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL SURVIVAL; CHEMOPROPHYLAXIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; LEWIS RAT; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECIES COMPARISON; STRIATONIGRAL DEGENERATION; TAUOPATHY; UPREGULATION;

ALPHA-SYNUCLEIN; ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; ENDOPLASMIC RETICULUM; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PHENYLBUTYRATES; ROTENONE; SUBSTANTIA NIGRA; TAUOPATHIES;

MUS; RATTUS;

EID: 34249814605     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04440.x     Document Type: Article

References (49)

1. Beal M. F. (2001) Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325 332.
2. Betarbet R., Sherer T., Mackenzie G., Garcia-Osuna M., Panov A. V. Geenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301 1306.
3. Betarbet R., Canet-Aviles R. M., Sherer T. et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22, 404 420.
4. Burrows J. A., Willis L. K. Perlmutter D. H. (2000) Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl Acad. Sci. USA 97, 1796 1801.
5. Butterfield P. G., Valanis B. G., Spencer P. S., Lindeman C. A. Nutt J. G. (1993) Environmental antecedents of young-onset Parkinson's disease. Neurology 43, 1150 1158.
6. Collins A. F., Pearson H. A., Giardina P., McDonagh K. T., Brusilow S. W. Dover G. J. (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85, 43 49.
7. Diaz-Corrales F. J., Asanuma M., Miyazaki I., Miyoshi K. Ogawa N. (2005) Rotenone induces aggregation of g-tubulin protein and subsequent disorganization of the centrosome: relevance to formation of inclusion bodies and neurodegeneration. Neuroscience 133, 117 135.
8. Dover G. J., Brusilow S. Charache S. (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84, 339 343.
9. Dunnett S. B. Björklund A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (Suppl. A32 A39.
10. Fischer H., Koenig U., Eckhart L. Tschachler E. (2002) Human caspase 12 has acquired deleterious mutations. Biochem. Biophys. Res. Commun. 293, 722 726.
11. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y. Mochizuki H. (2004) Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 24, 1865 1872.
12. Gao H.-M., Hong J.-S., Zhang W. Liu B. (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22, 782 790.
13. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L. Richardson R. J. (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346 1350.
14. Hashimoto M., Takeda A., Hsu L. J., Takenouchi T. Masliah E. (1999) Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28 849 28 852.
15. Hitomi J., Katayama T., Eguchi Y. et al. (2004) Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Aβ-induced cell death. J. Cell Biol. 165, 347 356.
16. Höglinger G. U., Carrard G., Michel P. P., Medja F., Lombès A., Ruberg M., Friguet B. Hirsch E. C. (2003a) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86, 1297 1307.
17. Höglinger G. U., Féger J., Prigent A., Michel P. P., Parain K., Champy P., Ruberg M., Oertel W. H. Hirsch E. C. (2003b) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491 502.
18. Höglinger G. U., Lannuzel A., Khondiker M. E. et al. (2005) The mitochondrial complex I inhibitor rotenone triggers a central tauopathy. J. Neurochem. 95, 930 939.
19. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891 902.
20. Inden M., Kitamura Y., Kondo J. et al. (2005a) Serofendic acid prevents 6-hyroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats. J. Neurochem. 95, 950 961.
21. Inden M., Kondo J., Kitamura Y., Takata K., Nishimura K., Taniguchi T., Sawada H. Shimohama S. (2005b) Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J. Pharmacol. Sci. 97, 203 211.
22. Inden M., Taira T., Kitamura Y. et al. (2006) PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol. Dis. 24, 144 158.
23. Javitch J. A., D'Amato R. J., Strittmatter S. M. Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,.3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. USA 82, 2173 2177.
24. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y. Taniguchi T. (2001) Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 59 67.
25. Katayama T., Imaizumi K., Sato N. et al. (1999) Presenilin-1 mutations downregulate the signaling pathway of the unfolded-protein response. Nat. Cell Biol. 1, 479 485.
26. Kettenmann H. Ransom B. R. (2005) Neuroglia, 2nd edn. Oxford University Press, Oxford.
27. Kitamura Y. Nomura Y. (2003) Stress proteins and glial function: possible therapeutic targets for neurodegenerative disorders. Pharmacol. Ther. 97, 35 53.
28. Kitamura Y., Shimohama S., Akaike A. Taniguchi T. (2000) The parkinsonian models: Invertebrates to mammals. Jpn. J. Pharmacol. 84, 237 243.
29. Kitamura Y., Inden M., Miyamura A., Kakimura J., Taniguchi T. Shimohama S. (2002) Possible involvement of both mitochondria- and endoplasmic reticulum-dependent caspase pathways in rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 333, 25 28.
30. Kubota K., Niinuma Y., Kaneko M. et al. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem. 97, 1259 1268.
31. Lapointe N., St-Hilaire M., Martinoli M.-G., Blanchet J., Gould P., Rouillard C. Cicchetti F. (2004) Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J. 18, 717 719.
32. Lewis J., McGowan E., Rockwood J. et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402 405.
33. Maestri N. E., Brusilow S. W., Clissold D. B. Bassett S. S. (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335, 855 859.
34. Mann V. M., Cooper J. M., Krige D., Daniel S. E., Schapira A. H. Marsden C. D. (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115, 333 342.
35. Matsuoka Y., Picciano M., Malester B. et al. (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158, 1345 1354.
36. Mizuno Y., Yoshino H., Ikebe S., Hattori N., Kobayashi T., Shimoda-Matsubayashi S., Matsumine H. Kondo T. (1998) Mitochondrial dysfunction in Parkinson's disease. Ann. Neurol. 44, S99 109.
37. Parker W. D. Jr., Boyson S. J. Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719 723.
38. Perlmutter D. H. (2002) Chemical chaperons: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr. Res. 52, 832 836.
39. Qi X., Hosoi T., Okuma Y., Kaneko M. Nomura Y. (2004) Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66, 899 908.
40. Ren Y., Liu W., Jiang H., Jiang Q. Feng J. (2005) Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280, 34 105 34 112.
41. Rubenstein R. C. Lyons B. M. (2001) Sodium 4-phenylbutyrate downregulates Hsc70 expression by facilitating mRNA degradation. Am. J. Physiol. Hung Cell. Mol. Physiol. 281, L43 L51.
42. Rubenstein R. C. Zeitlin P. L. (2000) Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am. J. Physiol. Cell. Physiol. 278, C259 267.
43. Schapira A. H. V., Cooper J. M., Dexter D., Jenner P., Clark J. B. Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
44. Sherer T. B., Kim J. H., Betarbet R. Geenamyre J. T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179, 9 16.
45. Shimohama S., Sawada H., Kitamura Y. Taniguchi T. (2003) Disease model: Parkinson's disease. Trends Mol. Med. 9, 360 365.
46. Taira T., Saito Y., Niki T., Iguchi-Ariga S. M. M., Takahashi K. Ariga H. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5, 213 218.
47. Thiruchelvam M., Richfieid E. K., Baggs R. B., Tank A. W. Cory-Slechta D. A. (2000) The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20, 9207 9214.
48. Tipton K. F. Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191 1206.
49. Zhu C., Vourc'h P., Fernagut P.-O., Fleming S. M., Lacan S., Dicarlo C. D., Seaman R. L. Chesselet M.-F. (2004) Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 478, 418 426.